European equities traded in the US as American depositary receipts were treading water late Thursday morning, edging 0.1% higher to 1,396.7 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and pharmaceutical company Novo Nordisk (NVO), which rose 4.7% and 3.3% respectively. They were followed by pharmaceutical company Ascendis Pharma (ASND) and telecommunications operator Telefonica (TEF), which were up 1.7% and 1.5% respectively.
The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and software firm SAP (SAP), which fell 2.7% and 2.3% respectively. They were followed by biotechnology companies argenx (ARGX) and Evaxion Biotech (EVAX), which dropped 2.1% and 0.9% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics (AKTX) and telecommunications operator Vodafone Group (VOD), which increased 5.2% and 3% respectively. They were followed by pharmaceutical companies Amarin (AMRN) and AstraZeneca (AZN), which advanced 2.8% and 1.4% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and Barclays (BCS), which lost 2.7% and 2.4% respectively. They were followed by biopharmaceutical companies TC Biopharm (TCBP) and Silence Therapeutics (SLN), which were down 1.8% and 1.2% respectively.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。